Why Is ALAMAR BIOSCIENCES I (ALMR) Stock Up Today?

Alamar Biosciences stock surged 30.65 percent to $36.57 on August 12 as multiple analysts raised price targets following a strong earnings report and updated guidance. The company reported 82 percent year-over-year revenue growth in Q2 2026 with a 60 percent gross margin and outlined a 2026 revenue outlook of $116 million to $120 million. These results and forward-looking metrics have triggered a wave of upgraded analyst ratings and increased investor interest.

What Happened

Stifel raised its price target for ALMR to $32 from $28, while JPMorgan increased its target to $35 from $32. BofA also raised its price target to $31 from $30. These upgrades followed the release of the earnings call transcript and a presentation detailing the company’s financial and operational progress. Alamar also announced an expansion of its Alzheimer’s Data Initiative, adding 86,000 samples to its research database. The CEO stated the company is well-positioned to sustain upcoming momentum, reinforcing the positive sentiment.

What The Data Shows

Alamar Biosciences has a market cap of $1.9 billion with trailing twelve-month revenue growth of 195.2 percent. Despite a net margin of -49.9 percent, the stock has traded between $18.84 and $29.43 over the past 52 weeks. The recent 30.65 percent intraday move has pushed the stock well beyond its 52-week high, indicating strong short-term momentum and a shift in market perception.

What To Watch

The company’s 2026 revenue guidance and ongoing partnerships in neurology will be key to monitoring future performance. Investors should also track the breadth of analyst coverage and any further price target adjustments in the coming weeks.